Garuda - Garba Rujukan Digital

Neoadjuvan Chemotheraphy Responses to Local Advanced Breast Cancer Patients at Dr Moh Hoesin Hospital Palembang Giovanno, Aldo; Mgs. Irsan Saleh; Nur Qodir; Mulawan Umar
Sriwijaya Journal of Medicine Vol. 3 No. 3 (2020): Sriwijaya Journal of Medicine
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/sjm.v3i3.131

Neoadjuvant Chemotherapy Responses on Locally Advanced Breast Cancer Patients in General Hospital of Mohammad Hoesin Palembang. Breast cancer is a malignancy which invaded breast tissue in the form of ductal or lobular. One most therapy which given is neoadjuvant chemotherapy. Neoadjuvant Chemotherapy can reduce tumor size so that surgery can be performed with good for breast removal with Modification of Radical Mastectomy (MRM) and Breast Conservative Therapy (BCT). This purposes from this research is to find out neoadjuvant chemotherapy response in Locally Advanced Breast Cancer Patients which is received chemotherapy treatment in RSUP dr Mohammad Hoesin Palembang. This observational descriptive study was conducted at RSUP Mohammad Hoesin Palembang in period between October until November 2019. The sample of this study was locally advanced breast Cancer patients who underwent chemotherapy that met the inclusion and exclusion criteria. The data were obtained by interviews and observed medical record from the patients which were then analyzed by univariate analysis using SPSS version 25. In this study there were 34 locally advanced breast cancer patients who fulfilled the inclusion and exclusion criteria. 24 of 34 patients (70,6%) received positive response and 10 of 34 patients (29,4%) received negative response. Many factors can determine the success of chemotherapy neoadjuvant one of them is a status of molecular subtype from breast cancer patients that must be managed with hormonal therapy and the provision of appropriate chemotherapy regimens also determine the success rate of neoadjuvan therapy in local breast cancer patients.

Hubungan Lama Penggunaan Kontrasepsi Hormonal dengan Kejadian Kanker Payudara pada Pasien di Poliklinik Bedah Onkologi RSUP Dr. Mohammad Hoesin Palembang pada September – Oktober 2016 Karisya Tri Andini; Nur Qodir; Mutiara Budi Azhar
Majalah Kedokteran Sriwijaya Vol 49, No 1 (2017): Majalah Kedokteran Sriwijaya
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36706/mks.v49i1.8322

Kanker payudara merupakan salah satu penyebab utama kematian wanita di seluruh dunia.Terdapat beberapa faktor risiko yang memengaruhi terjadinya kanker payudara, salah satunya penggunaan kontrasepsi hormonal jangka panjang.Penelitian ini bertujuan untuk mengetahui hubungan lama penggunaan kontrasepsi hormonal dengan kejadian kanker payudara pada pasien di Poliklinik Bedah Onkologi RSUP Dr. Mohammad Hoesin Palembang pada September–Oktober 2016.Penelitian ini merupakan penelitian analitik observasional dengan desain cross sectional. Sampel penelitian adalah pasien di Poliklinik Bedah Onkologi RSUP Dr. Mohammad Hoesin Palembang pada September-Oktober 2016 dengan sampel minimal sebanyak 146 sampel. Data diolah dengan SPSS dan dianalisis menggunakan uji Chi-square.Pada penelitian ini ditemukan 50,7% kasus kanker payudara. Pengguna kontrasepsi oral 23,9%, injeksi 1 bulan 28,3%, injeksi 3 bulan 28,7%, dan implan 19,1%. Dari hasil analisis bivariat uji Chi-squareditemukan hubungan penggunaan kontrasepsi hormonal(p=0,000), oral(p=0,026), injeksi 3 bulan(p=0,035), implan(p=0,035) lebih dari lima tahun dengan kejadian kanker payudara. Tidak ada hubungan penggunaan kontrasepsi injeksi 1 bulan lebih dari lima tahun dengan kejadian kanker payudara(p=0,465). Terdapat hubungan penggunaan kontrasepsi hormonal, oral, injeksi 3 bulan, dan implan lebih dari lima tahun dan tidak terdapat hubungan penggunaan kontrasepsi injeksi 1 bulan lebih dari lima tahun dengan kejadian kanker payudara.

Karakteristik Pasien Karsinoma Tiroid Papiler di Rumah Sakit Umum Pusat Dr. Mohammad Hoesin Periode Januari-Desember 2016 M Ali Ridho; Nur Qodir; Triwani Triwani
Majalah Kedokteran Sriwijaya Vol 50, No 4 (2018): Majalah Kedokteran Sriwijaya
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36706/mks.v50i4.8564

Karsinoma tiroid merupakan keganasan pada kelenjar endokrin dan diduga merupakan 1,1% dari seluruh keganasan yang ada pada manusia. Tahun 2008, ditemukan sekitar 213.000 kasus baru di seluruh dunia dengan angka insiden sekitar 3,1/100.000 populasi. Karsinoma tiroid papiller (KTP) merupakan karsinoma tiroid yang paling sering terjadi (sekitar 80%) dari seluruh kasus.Penelitian ini dilakukan untuk mengetahui karakteristik dari karsinoma tiroid papiler berdasarkan sosiodemografi pasien dan masing-masing faktor risiko penyakitnya.Jenis penelitian bersifat observasional deskriptif dengan menggunakan data sekunder dari rekam medik sebagai subjek penelitian di Departemen Bedah RSUP Dr. Mohammad Hoesin Palembang. Dari 61 subjek penelitian, menurut jenis kelamin didapatkan wanita dengan persentase 83,6% (N=51). Berdasarkan usia, paling tinggi yaitu pada kelompok usia 25-34 tahun dengan persentase 23% (N=14). Berdasarkan tempat tinggal, didapatkan daerah perkotaan yaitu 65,6% (N=40) dan dataran rendah sebanyak 88,5% (N=54). Menurut varian karsinoma, paling banyak yaitu varian follicular dengan persentase 52,5% (N=32). Menurut penyakit terdahulunya didapatkan paling banyak yaitu goiter dengan persentase 88,5% (N=54). Menurut adanya paparan radiasi sebanyak 100% tidak pernah terpapar. Berdasarkan gejala klinis ditemukan sebanyak 67,2% (N=41) tidak terdapat gejala klinis. Menurut riwayat keluarga didapatkan 100% tidak ada keluarga yang menderita penyakit keganasan tiroid.Karsinoma tiroid papiler banyak ditemukan pada wanita dan usia paling banyak yaitu 25-34 tahun dengan distribusi tempat tinggal paling banyak pada perkotaan dan dataran rendah (pantai). Varian paling banyak yaitu follicular dan paling banyak didahului oleh goiter tanpa disertai oleh pengaruh dari radiasi.Sebagian besar pasien tidak mengeluh adanya gejala dan semuanya tidak memliki riwayat keluarga penderita keganasan tiroid.

Effects of Neoadjuvant Fluorouracyl-Adriamycin- Cytoxan (FAC) Chemotherapy Response to CD4 + Serum Levels In Breast Cancer Ade Permana; Benny Kusuma; Nur Qodir; Legiran
Sriwijaya Journal of Surgery Vol. 1 No. 1 (2018): Sriwijaya Journal of Surgery
Publisher : Surgery Department, Faculty of Medicine Universitas Sriwijaya

Introduction. CD4+ T-helper has an important role in immune system modulation especially to maintain long-term anti tumor effect. CD4+ also serves to activate CD8+ for destroyed the tumor cells. It was expected there were role of immunity on tumor growth and response of breast cancer chemotherapy to CD4+ levels serum. Furthermore, this study was aimed to investigate the effects of neoadjuvant chemotherapy on CD4+ levels in patients with locally advanced breast cancer at General Hospital Dr. Mohammad Hoesin Palembang. Method. This study was a non-comparable clinical trial by looking at serum CD4+ levels in patients with locally advanced breast cancer before and after neoadjuvant chemotherapy. Results. Of the 30 subjects the subject age ranged from 33-66 years with an average of 45 years. There were 17 patients with contraception history (56.7%), 13 patients with family history of breast cancer (43.3%). From this study, it was obtained 23 patients with good chemotherapy response (76.7%) and there were 7 patients who had poor chemotherapy response after neoadjuvan chemotherapy (23.3%). Paired t-test analysis showed that there was a significant difference in mean CD4+ count before and after neoadjuvan chemotherapy. At the CD4+ level before chemotherapy 775.55 had a sensitivity of 60% and a specificity of 57% (cut of point). While CD4+ levels after chemotherapy 470.85 with sensitivity of 60% and specificity of 57%. Conclusion. CD4+ pre-chemotherapy examination had a sensitivity score of 60% and a specificity of 57% in predicting neoadjuvant chemotherapy response.

Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Friyoga Syahril; Wirdah, Aisyah; Nur Qodir; Irfanuddin; Irsan Saleh; Yenny Dian Andayani; Mediarty; Norman Djamaluddin
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 2 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i2.924

Background: Breast cancer is a malignancy caused by the continuous uncontrolled growth of the component cells of the ducts or lobules of the breast gland. Globally, breast cancer is the second leading cause of death in women. Nigella sativa contains substances thymoquinone. Thymoquinone can inhibit the progression of cancer through anti-inflammatory, anti-oxidant mechanisms, inhibit proliferation, trigger apoptosis, and prevent angiogenesis. Chronic inflammation in breast cancer is mediated by one of them is TNF-alpha tumors. Elevated levels of TNF-α have a significant association with poor prognosis and progression of breast cancer. This study aims to determine the effectiveness of the additional Nigella sativa in declining TNF-α levels in breast cancer patients at Dr. Mohammad Hoesin General Hospital Palembang. Methods: This research used a randomized, open clinical trial design, which was carried out at the internal medicine hematology-oncology medical polyclinic and the surgical oncology polyclinic of Dr. Mohammad Hoesin General Hospital Palembang from January 2023 to October 2023. Data processing for data analysis used SPSS version 26 for Windows. Results: There were 36 research subjects followed during the study period and received Doxorubicin chemotherapy and cyclophosphamide (AC), which were divided into treatment groups of 18 people (chemotherapy with the addition of Nigella sativa @600 mg 2x2 capsule/ day and a control group of 18 people. A TNF-alpha examination was carried out before and after to assess the comparison before and after. From the results, it was found that TNF-alpha levels in the treatment group showed a decrease in TNF-alpha with a p-value <0.001. Conclusion: The addition of Nigella sativa has the effect of reducing TNF-alpha in breast cancer patients receiving AC chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang.

Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia Friyoga Syahril; Wirdah, Aisyah; Nur Qodir; Irfanuddin; Irsan Saleh; Yenny Dian Andayani; Mediarty; Norman Djamaluddin
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 2 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i2.924

Background: Breast cancer is a malignancy caused by the continuous uncontrolled growth of the component cells of the ducts or lobules of the breast gland. Globally, breast cancer is the second leading cause of death in women. Nigella sativa contains substances thymoquinone. Thymoquinone can inhibit the progression of cancer through anti-inflammatory, anti-oxidant mechanisms, inhibit proliferation, trigger apoptosis, and prevent angiogenesis. Chronic inflammation in breast cancer is mediated by one of them is TNF-alpha tumors. Elevated levels of TNF-α have a significant association with poor prognosis and progression of breast cancer. This study aims to determine the effectiveness of the additional Nigella sativa in declining TNF-α levels in breast cancer patients at Dr. Mohammad Hoesin General Hospital Palembang. Methods: This research used a randomized, open clinical trial design, which was carried out at the internal medicine hematology-oncology medical polyclinic and the surgical oncology polyclinic of Dr. Mohammad Hoesin General Hospital Palembang from January 2023 to October 2023. Data processing for data analysis used SPSS version 26 for Windows. Results: There were 36 research subjects followed during the study period and received Doxorubicin chemotherapy and cyclophosphamide (AC), which were divided into treatment groups of 18 people (chemotherapy with the addition of Nigella sativa @600 mg 2x2 capsule/ day and a control group of 18 people. A TNF-alpha examination was carried out before and after to assess the comparison before and after. From the results, it was found that TNF-alpha levels in the treatment group showed a decrease in TNF-alpha with a p-value <0.001. Conclusion: The addition of Nigella sativa has the effect of reducing TNF-alpha in breast cancer patients receiving AC chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang.

Title

Found 6 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 6 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 6 Documents
Search